SatyaRx Pharma Innovations

SatyaRx Pharma Innovations is a Bangalore-based biotechnology company focused on developing next-generation cancer therapeutics by targeting the DNA damage response (DDR) pathway. The company's primary focus is on the Proliferating Cell Nuclear Antigen (PCNA), a master regulator of DNA replication and repair that is often overexpressed in cancer cells. By utilizing a proprietary platform to identify small molecule inhibitors that disrupt specific protein-protein interactions of PCNA, SatyaRx aims to create highly selective treatments for various solid tumors. The company was founded by experienced scientists from the academic and pharmaceutical sectors and has received support from prominent Indian incubator networks and government grants.